Helsinn Group
Melanie Rolli has an extensive work experience in various roles and positions. Melanie currently holds the position of Chief Executive Officer at Helsinn Group since January 2023. Prior to this, they served as the Chief Operating Officer at Helsinn Group from June 2022 to December 2022.
Melanie has also worked as a Non Executive Director at Baccinex since November 2020 and at ERYTECH Pharma from March 2020 to May 2023. Melanie held the role of Non Executive Director at Rivia from December 2021 to December 2022.
Previously, Melanie was the Chief Executive Officer at AELIX Therapeutics from April 2021 to December 2021. Melanie also held multiple positions at PIQUR Therapeutics AG, including Chief Executive Officer from May 2019 to April 2021, Chief Operating Officer from June 2018 to April 2019, and Chief Medical Officer from March 2017 to April 2019.
Before joining PIQUR Therapeutics AG, they had various roles at Novartis, including Global Head Medical Safety, Group Drug Development from July 2016 to March 2017. Melanie was also the Global Head Integrated Medical Safety, Oncology from August 2014 to July 2016 and the Therapeutic Area Safety Leader_Critical Care, Drug Safety and Epidemiology, VP from January 2013 to August 2014.
Melanie'swork at Novartis also included roles like Chief Scientific Officer a.i. GEM, Head of Medical Affairs, Group Emerging Markets, and Different Global and Local Roles from 2003 to 2011.
Melanie Rolli started their career as a Research Fellow at The Scripps Research Institute from 2001 to 2003. Melanie also participated in a Women's luncheon at GLG Institute in 2014.
Melanie Rolli earned their Medical Doctor degree with a specialization in Gyn/Obs and Pharmacology at Heidelberg University from 1992 to 1999. Melanie then pursued a postdoctoral research position at Scripps Research from 2001 to 2003, specializing in MEM. In 2015, they attended Harvard Business School Executive Education, earning a degree in Finance for non-financial professionals. Recently, in 2021, they completed an Executive Education program in Business Administration and Management, General at Imperial College London.
This person is not in any offices
Helsinn Group
1 followers
Welcome to Helsinn’s LinkedIn page. This account shall only be used to share (*) news concerning Helsinn. We would like to emphasize that due to the highly regulated nature of the pharma industry, we cannot engage with you online in any discussions concerning our or other companies’ products and/or services, and/or treatment options. It is best to hold such discussions and to seek guidance privately from your healthcare professional Helsinn is a fully integrated, global biopharma company headquartered in Lugano, Switzerland. It is focused on improving the lives of cancer patients all over the world with a leading position in cancer supportive care and an innovative pipeline of cancer therapeutics. Helsinn is a third-generation family-owned company, that since 1976 has been focused on improving the lives of patients, guided by core values of respect, integrity and quality. It operates a unique licensing business model with integrated drug development and manufacturing capabilities. Helsinn has a commercial presence in 190 countries either directly, with operating subsidiaries in the U.S. and China, or via its long-standing trusted partners. Helsinn also has a fully integrated supply chain and product development through its subsidiary in Ireland, Helsinn Birex Pharmaceuticals Ltd. If you are interested in joining Helsinn or one of our affiliates, please visit helsinn.com. Applications should only be submitted via the appropriate country portal under “Working for Helsinn”. Any other sources of communications are unauthorized, and we discourage candidates from replying to suspect employment offers received through unofficial channels. If you are experiencing problems or have questions, please contact: Switzerland: info-HHC@helsinn.com, U.S.: HTU-HR@helsinn.com, Ireland: info-hbp@helsinn.com. [These emails are NOT an application channel: CVs and sensitive information sent inappropriately to the above emails will NOT be considered or processed, and will be DELETED]